Skip to Content

Promising effect of Zolbetuximab and mFOLFOX6 Combination For Gastroesophageal Junction Adenocarcinoma

The SPOTLIGHT study, presented at ASCO GI, indicates promising effects of combining Zolbetuximab with mFOLFOX6 chemotherapy as first-line treatment for people with advanced gastroesophageal junction adenocarcinoma resistant to surgery. Kohei Shitara from the National Cancer Center Hospital East in Chiba, Japan, presents the results in this MEDtalk.

Kohei Shitara

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top